{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:00:39Z","timestamp":1790402439590,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016190","name":"Trond Mohn stiftelse","doi-asserted-by":"publisher","award":["TMS2022STG01"],"award-info":[{"award-number":["TMS2022STG01"]}],"id":[{"id":"10.13039\/100016190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6bergstiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["255690"],"award-info":[{"award-number":["255690"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsradet","doi-asserted-by":"publisher","award":["2022-01151"],"award-info":[{"award-number":["2022-01151"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsradet","doi-asserted-by":"publisher","award":["2021-02693"],"award-info":[{"award-number":["2021-02693"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["211790PJ"],"award-info":[{"award-number":["211790PJ"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["21149PJ"],"award-info":[{"award-number":["21149PJ"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jtho.2024.12.026","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T19:20:31Z","timestamp":1735586431000},"page":"625-640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC"],"prefix":"10.1016","volume":"20","author":[{"given":"Amanda","family":"Lindberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Muhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Hellberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Artursson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Backman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Hekmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lindskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Brunnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Botling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Mezheyeuski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Brostr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Gulyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas","family":"K\u00e4rre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Micke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-7256","authenticated-orcid":false,"given":"Carina","family":"Strell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.12.026_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jtho.2024.12.026_bib2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.12.026_bib3","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.026_bib4","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.026_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","article-title":"PD-Loma: a cancer entity with a shared sensitivity to the PD-1\/PD-L1 pathway blockade","volume":"120","author":"Hirsch","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2024.12.026_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10147-019-01498-8","article-title":"Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition","volume":"25","author":"Mishima","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.026_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2024.12.026_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2022.100346","article-title":"Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: a comparison of the regulatory approvals in Europe and the United States","volume":"33","author":"Zaim","year":"2022","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.jtho.2024.12.026_bib9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"De Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.026_bib10","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab Plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.026_bib11","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.026_bib12","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jtho.2024.05.376","article-title":"Benefit with no target: long-term outcomes of chemoimmunotherapy in \u201cPD-L1 negative\u201d NSCLC","volume":"19","author":"Perrone","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.026_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1078-0432.CCR-21-2649","article-title":"Association of PD-1\/PD-L1 co-location with immunotherapy outcomes in non-small cell lung cancer","volume":"28","author":"Gavrielatou","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.026_bib14","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1200\/JCO.22.01748","article-title":"Functional engagement of the PD-1\/PD-L1 complex But not PD-L1 expression is highly predictive of patient response to immunotherapy in non-small-cell lung cancer","volume":"41","author":"S\u00e1nchez-Magraner","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.026_bib15","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1038\/s41598-018-23582-1","article-title":"Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes","volume":"8","author":"Klaesson","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.026_bib16","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/ijc.27518","article-title":"CD99 is a novel prognostic stromal marker in non-small cell lung cancer","volume":"131","author":"Edlund","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2024.12.026_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2018.12.022","article-title":"Prognostic impact of tumor cell programmed death ligand 1 expression and immune cell infiltration in NSCLC","volume":"14","author":"Edlund","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.026_bib18","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s00262-020-02825-z","article-title":"PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung","volume":"70","author":"Goldmann","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2024.12.026_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.026_bib20","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1097\/JTO.0b013e3182295917","article-title":"Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer","volume":"6","author":"Micke","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.026_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41597-023-02074-6","article-title":"An integrated single-cell transcriptomic dataset for non-small cell lung cancer","volume":"10","author":"Prazanowska","year":"2023","journal-title":"Sci Data"},{"key":"10.1016\/j.jtho.2024.12.026_bib22","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.026_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"key":"10.1016\/j.jtho.2024.12.026_bib24","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/modpathol.2017.59","article-title":"PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability","volume":"30","author":"Brunnstr\u00f6m","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2024.12.026_bib25","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.21037\/tlcr.2017.10.05","article-title":"The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?","volume":"6","author":"Troncone","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.026_bib26","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.026_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/path.5772","article-title":"Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer","volume":"255","author":"Backman","year":"2021","journal-title":"J Pathol"},{"key":"10.1016\/j.jtho.2024.12.026_bib28","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202644","article-title":"JAML promotes CD8 and \u03b3\u03b4 T cell antitumor immunity and is a novel target for cancer immunotherapy","volume":"218","author":"McGraw","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtho.2024.12.026_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112040","article-title":"JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells","volume":"42","author":"Eschweiler","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2024.12.026_bib30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06231-0","article-title":"B-cell-specific checkpoint molecules that regulate anti-tumour immunity","volume":"619","author":"Bod","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.026_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.resinv.2024.01.011","article-title":"Immunotherapy for non-small cell lung cancer","volume":"62","author":"Kagamu","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.jtho.2024.12.026_bib32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019.","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2024.12.026_bib33","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-23-3932","article-title":"Spatially informed gene signatures for response to immunotherapy in melanoma","volume":"30","author":"Aung","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.026_bib34","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/s41467-024-46450-1","article-title":"Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors","volume":"15","author":"Gil-Jimenez","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.026_bib35","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.026_bib36","article-title":"A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma","volume":"12","author":"Yang","year":"2022","journal-title":"Sci Rep"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:27:46Z","timestamp":1762550866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424025474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1556086424025474"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.026","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}